‘Global Translational Regenerative Medicine Market Worth $14.5bn In 2021’ Says Visiongain Report

22 August 2018
Pharma

Visiongain’s new report Global Translational Regenerative Medicine Market Prospects 2017-2027: Stem Cell Therapies, Tissue Engineered Products, Gene Therapies indicates that the Global Translational Regenerative Medicine Market will see $14.5bn in spending in 2021.

The Global Translational Regenerative Medicine market is expected to grow significantly over the forecast period. The Global Translational Regenerative Medicine market was valued at $5.8bn in 2016. Visiongain forecasts this market to increase to $14.5bn in 2021. The market is estimated to grow at a CAGR of 19.9% in the first half of the forecast period and 17.7% from 2016 to 2027.

The lead analyst of the report said: “Growth in the global TRM market will be fuelled particularly by stem cell therapies and tissue engineering advancements, as well as the emergence of commercial gene therapy products. The improvements in regulation of stem cell research on a regional level will increase its attractiveness. We note that advancements such as 3D bioprinting should enable the development of tissues which can be used for toxicology testing purposes.

Furthermore, strong government support for regenerative medicine particularly in countries such as China and South Korea, as well as the accelerated regulatory pathway for regenerative medicine in Japan will fuel growth in stem cell therapies.”

The 316-page report contains 107 tables and 66 figures that add visual analysis in order to explain the developing trends within the Global Translational Regenerative Medicine Market.

Visiongain provides revenue forecasts for the period 2017-2027 for the global market as well as the leading submarkets: Stem Cell Therapies, Tissue Engineered Products and Gene Therapies.

Furthermore, this report provides revenue forecasts for these leading products: Osteocel Plus, Trinity ELITE, TEMCELL /Prochymalm, Apligraf, Dermagraft, Epifix, ReCell, Neovasculgen, Glybera (alipogene tiparvovec), IMLYGIC (talimogene laherparepvec).

The 316-page report offers market forecasts and analysis for: the US, Europe, Asia-Pacific and the Rest of the World. In addition, this report discusses the leading companies in the Translational Regenerative Medicine Market.

The Global Translational Regenerative Medicine Market Prospects 2017-2027: Stem Cell Therapies, Tissue Engineered Products, Gene Therapies report will be of value to anyone who wants to better understand the translational regenerative medicine market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the translational regenerative medicine industry.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever